Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aldeyra Therapeu (ALDX)

Aldeyra Therapeu (ALDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 295,156
  • Shares Outstanding, K 38,633
  • Annual Sales, $ 0 K
  • Annual Income, $ -60,830 K
  • 60-Month Beta 2.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.74
Trade ALDX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.28
  • Number of Estimates 1
  • High Estimate -0.28
  • Low Estimate -0.28
  • Prior Year -0.69
  • Growth Rate Est. (year over year) +59.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.61 +15.58%
on 09/24/20
8.70 -12.18%
on 10/19/20
+0.86 (+12.68%)
since 09/23/20
3-Month
5.53 +38.16%
on 09/08/20
8.70 -12.18%
on 10/19/20
+1.31 (+20.70%)
since 07/23/20
52-Week
1.48 +416.22%
on 03/17/20
8.70 -12.18%
on 10/19/20
+1.71 (+28.84%)
since 10/23/19

Most Recent Stories

More News
Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting

--Clinical Relevance Demonstrated with Responder Analyses

ALDX : 7.64 (+0.66%)
Has Aldeyra Therapeutics (ALDX) Outpaced Other Medical Stocks This Year?

Is (ALDX) Outperforming Other Medical Stocks This Year?

ALDX : 7.64 (+0.66%)
Heron's (HRTX) Pain Drug Zynrelef Gets EU Approval, Shares Up

Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.

IRWD : 9.64 (+1.58%)
BLRX : 1.5500 (unch)
ALDX : 7.64 (+0.66%)
HRTX : 16.50 (+0.36%)
Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU

The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

IRWD : 9.64 (+1.58%)
PCRX : 55.47 (+2.14%)
INFI : 1.1800 (unch)
ALDX : 7.64 (+0.66%)
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?

Is (ALDX) Outperforming Other Medical Stocks This Year?

ALDX : 7.64 (+0.66%)
Aldeyra to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., Chief Financial Officer Joshua Reed, and Chief Commercial Officer David McMullin will...

MHMNF : 54.5000 (unch)
ALDX : 7.64 (+0.66%)
Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting one-on-one meetings at the following investor conferences:

ALDX : 7.64 (+0.66%)
Aldeyra Receives Study May Proceed Letter from FDA to Initiate Clinical Trial of ADX-629 in COVID-19 Patients

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial evaluating...

ALDX : 7.64 (+0.66%)
Savara to Stop Study on Molgradex for NTM Lung Infection

Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.

JAZZ : 150.26 (-0.61%)
BLRX : 1.5500 (unch)
ALDX : 7.64 (+0.66%)
SVRA : 1.1800 (+1.72%)
Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics

Zacks.com featured highlights include: Fulgent Genetics, Primoris Services, Niu Technologies, Surface Oncology and Aldeyra Therapeutics

PRIM : 19.96 (+1.22%)
ALDX : 7.64 (+0.66%)
FLGT : 35.85 (+1.41%)
SURF : 9.57 (+8.38%)
NIU : 27.35 (-1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 7.99
1st Resistance Point 7.82
Last Price 7.64
1st Support Level 7.36
2nd Support Level 7.07

See More

52-Week High 8.70
Last Price 7.64
Fibonacci 61.8% 5.94
Fibonacci 50% 5.09
Fibonacci 38.2% 4.24
52-Week Low 1.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar